SlideShare una empresa de Scribd logo
1 de 53
Descargar para leer sin conexión
Acute and Chronic
Inflammation
Pandian M.
Dept.of Physiology
Assigned Reading
Introduction
 Injurious stimuli cause a protective vascular connective
tissue reaction called “inflammation”
 Dilute
 Destroy
 Isolate
 Initiate repair
 Acute and chronic forms
Acute inflammation
 Immediate and early response to tissue injury (physical,
chemical, microbiologic, etc.)
 Vasodilation
 Vascular leakage and edema
 Leukocyte emigration (mostly PMNs)
Vasodilation
 Brief arteriolar vasoconstriction followed by
vasodilation
 Accounts for warmth and redness
 Opens microvascular beds
 Increased intravascular pressure causes an early
transudate (protein-poor filtrate of plasma) into
interstitium (vascular permeability still not increased yet)
Vascular leakage
 Vascular permeability (leakiness) commences
 Transudate gives way to exudate (protein-rich)
 Increases interstitial osmotic pressure contributing to
edema (water and ions)
Vascular leakage
 Five mechanisms known to cause vascular leakiness
 Histamines, bradykinins, leukotrienes cause an early, brief
(15 – 30 min.) immediate transient response in the form of
endothelial cell contraction that widens intercellular gaps
of venules (not arterioles, capillaries)
Vascular leakage
 Cytokine mediators (TNF, IL-1) induce endothelial cell
junction retraction through cytoskeleton reorganization (4
– 6 hrs post injury, lasting 24 hrs or more)
 Severe injuries may cause immediate direct endothelial
cell damage (necrosis, detachment) making them leaky
until they are repaired (immediate sustained response), or
may cause delayed damage as in thermal or UV injury,
Vascular leakage
 (cont’d) or some bacterial toxins (delayed prolonged
leakage)
 Marginating and endothelial cell-adherent leukocytes may
pile-up and damage the endothelium through activation
and release of toxic oxygen radicals and proteolytic
enzymes (leukocyte-dependent endothelial cell injury)
making the vessel leaky
Vascular leakage
 Certain mediators (VEGF) may cause increased transcytosis
via intracellular vesicles which travel from the luminal to
basement membrane surface of the endothelial cell
 All or any combination of these events may occur in
response to a given stimulus
Leukocyte cellular events
 Leukocytes leave the vasculature
routinely through the following
sequence of events:
 Margination and rolling
 Adhesion and transmigration
 Chemotaxis and activation
 They are then free to participate in:
 Phagocytosis and degranulation
 Leukocyte-induced tissue injury
Margination and Rolling
 With increased vascular permeability,
fluid leaves the vessel causing
leukocytes to settle-out of the central
flow column and “marginate” along
the endothelial surface
 Endothelial cells and leukocytes have
complementary surface adhesion
molecules which briefly stick and
release causing the leukocyte to roll
along the endothelium like a
tumbleweed until it eventually comes
to a stop as mutual adhesion reaches a
peak
Margination and Rolling
 Early rolling adhesion mediated by selectin family:
 E-selectin (endothelium), P-selectin (platelets,
endothelium), L-selectin (leukocytes) bind other surface
molecules (i.e.,CD34, Sialyl-Lewis X-modified GP) that are
upregulated on endothelium by cytokines (TNF, IL-1) at
injury sites
Adhesion
 Rolling comes to a stop and adhesion
results
 Other sets of adhesion molecules
participate:
 Endothelial: ICAM-1, VCAM-1
 Leukocyte: LFA-1, Mac-1, VLA-4
(ICAM-1 binds LFA-1/Mac-1, VCAM-1 binds VLA-4)
 Ordinarily down-regulated or in an
inactive conformation, but inflammation
alters this
Transmigration (diapedesis)
 Occurs after firm adhesion within the systemic venules
and pulmonary capillaries via PECAM –1 (CD31)
 Must then cross basement membrane
 Collagenases
 Integrins
Transmigration (diapedesis)
 Early in inflammatory response mostly PMNs, but as
cytokine and chemotactic signals change with
progression of inflammatory response, alteration of
endothelial cell adhesion molecule expression activates
other populations of leukocytes to adhere (monocytes,
lymphocytes, etc)
Chemotaxis
 Leukocytes follow chemical gradient
to site of injury (chemotaxis)
 Soluble bacterial products
 Complement components (C5a)
 Cytokines (chemokine family e.g., IL-8)
 LTB4 (AA metabolite)
 Chemotactic agents bind surface
receptors inducing calcium
mobilization and assembly of
cytoskeletal contractile elements
Chemotaxis and Activation
 Leukocytes:
 extend pseudopods with overlying surface adhesion
molecules (integrins) that bind ECM during chemotaxis
 undergo activation:
 Prepare AA metabolites from phospholipids
 Prepare for degranulation and release of lysosomal enzymes
(oxidative burst)
 Regulate leukocyte adhesion molecule affinity as needed
Phagocytosis and
Degranulation
 Once at site of injury, leukocytes:
 Recognize and attach
 Engulf (form phagocytic vacuole)
 Kill (degrade)
Recognition and Binding
 Opsonized by serum complement, immunoglobulin (C3b,
Fc portion of IgG)
 Corresponding receptors on leukocytes (FcR, CR1, 2, 3)
leads to binding
Phagocytosis and
Degranulation
 Triggers an oxidative burst (next slide) engulfment and
formation of vacuole which fuses with lysosomal granule
membrane (phagolysosome)
 Granules discharge within phagolysosome and
extracellularly (degranulation)
Oxidative burst
 Reactive oxygen species formed through oxidative burst
that includes:
 Increased oxygen consumption
 Glycogenolysis
 Increased glucose oxidation
 Formation of superoxide ion
 2O2 + NADPH  2O2
-rad + NADP+ + H+
(NADPH oxidase)
 O2 + 2H+  H2O2 (dismutase)
Reactive oxygen species
 Hydrogen peroxide alone insufficient
 MPO (azurophilic granules) converts hydrogen peroxide
to HOCl- (in presence of Cl- ), an oxidant/antimicrobial
agent
 Therefore, PMNs can kill by halogenation, or
lipid/protein peroxidation
Degradation and Clean-up
 Reactive end-products only active within phagolysosome
 Hydrogen peroxide broken down to water and oxygen by
catalase
 Dead microorganisms degraded by lysosomal acid
hydrolases
Leukocyte granules
 Other antimicrobials in leukocyte granules:
 Bactericidal permeability increasing protein (BPI)
 Lysozyme
 Lactoferrin
 Defensins (punch holes in membranes)
Leukocyte-induced tissue
injury
 Destructive enzymes may enter extracellular space in
event of:
 Premature degranulation
 Frustrated phagocytosis (large, flat)
 Membranolytic substances (urate crystals)
 Persistent leukocyte activation (RA, emphysema)
Defects of leukocyte function
 Defects of adhesion:
 LFA-1 and Mac-1 subunit defects lead to impaired adhesion
(LAD-1)
 Absence of sialyl-Lewis X, and defect in E- and P-selectin
sugar epitopes (LAD-2)
 Defects of chemotaxis/phagocytosis:
 Microtubule assembly defect leads to impaired locomotion
and lysosomal degranulation (Chediak-Higashi Syndrome)
Defects of leukocyte function
 Defects of microbicidal activity:
 Deficiency of NADPH oxidase that generates superoxide,
therefore no oxygen-dependent killing mechanism (chronic
granulomatous disease)
Chemical mediators
 Plasma-derived:
 Complement, kinins, coagulation factors
 Many in “pro-form” requiring activation (enzymatic
cleavage)
 Cell-derived:
 Preformed, sequestered and released (mast cell histamine)
 Synthesized as needed (prostaglandin)
Chemical mediators
 May or may not utilize a specific cell
surface receptor for activity
 May also signal target cells to release
other effector molecules that either
amplify or inhibit initial response
(regulation)
 Are tightly regulated:
 Quickly decay (AA metabolites), are
inactivated enzymatically (kininase), or
are scavenged (antioxidants)
Specific mediators
 Vasoactive amines
 Histamine: vasodilation and venular endothelial cell
contraction, junctional widening; released by mast cells,
basophils, platelets in response to injury (trauma, heat),
immune reactions (IgE-mast cell FcR), anaphylatoxins
(C3a, C5a fragments), cytokines (IL-1, IL-8),
neuropeptides, leukocyte-derived histamine-releasing
peptides
Specific mediators
 Serotonin: vasodilatory effects similar to those of
histamine; platelet dense-body granules; release triggered
by platelet aggregation
 Plasma proteases
 Clotting system
 Complement
 Kinins
Clotting cascade
 Cascade of plasma proteases
 Hageman factor (factor XII)
 Collagen, basement membrane, activated platelets
converts XII to XIIa (active form)
 Ultimately converts soluble fibrinogen to insoluble fibrin
clot
 Factor XIIa simultaneously activates the “brakes” through
the fibrinolytic system to prevent continuous clot
propagation
Kinin system
 Leads to formation of bradykinin from cleavage of
precursor (HMWK)
 Vascular permeability
 Arteriolar dilation
 Non-vascular smooth muscle contraction (e.g., bronchial
smooth muscle)
 Causes pain
 Rapidly inactivated (kininases)
Complement system
 Components C1-C9 present in inactive
form
 Activated via classic (C1) or alternative
(C3) pathways to generate MAC (C5 – C9)
that punch holes in microbe membranes
 In acute inflammation
 Vasodilation, vascular permeability, mast cell
degranulation (C3a, C5a)
 Leukocyte chemotaxin, increases integrin
avidity (C5a)
 As an opsonin, increases phagocytosis (C3b,
C3bi)
Specific Mediators
 Arachidonic acid metabolites (eicosanoids)
 Prostaglandins and thromboxane: via cyclooxygenase
pathway; cause vasodilation and prolong edema; but also
protective (gastric mucosa); COX blocked by aspirin and
NSAIDS
Specific Mediators
 Leukotrienes: via lipoxygenase pathway; are chemotaxins,
vasoconstrictors, cause increased vascular permeability,
and bronchospasm
 PAF (platelet activating factor)
 Derived also from cell membrane phospholipid, causes
vasodilation, increased vascular permeability, increases
leukocyte adhesion (integrin conformation)
More specific mediators
 Cytokines
 Protein cell products that act as a message to other cells,
telling them how to behave.
 IL-1, TNF- and -, IFN- are especially important in
inflammation.
 Increase endothelial cell adhesion molecule expression,
activation and aggregation of PMNs, etc., etc., etc.
Specific mediators
 Nitric Oxide
 short-acting soluble free-radical gas with many functions
 Produced by endothelial cells, macrophages, causes:
 Vascular smooth muscle relaxation and vasodilation
 Kills microbes in activated macrophages
 Counteracts platelet adhesion, aggregation, and degranulation
Specific mediators
 Lysosomal components
 Leak from PMNs and macrophages after demise, attempts
at phagocytosis, etc.
 Acid proteases (only active within lysosomes).
 Neutral proteases such as elastase and collagenase are
destructive in ECM.
 Counteracted by serum and ECM anti-proteases.
Possible outcomes of acute
inflammation
 Complete resolution
 Little tissue damage
 Capable of regeneration
 Scarring (fibrosis)
 In tissues unable to regenerate
 Excessive fibrin deposition organized into fibrous tissue
Outcomes (cont’d)
 Abscess formation occurs with some bacterial or fungal
infections
 Progression to chronic inflammation (next)
Chronic inflammation
 Lymphocyte, macrophage, plasma cell
(mononuclear cell) infiltration
 Tissue destruction by inflammatory
cells
 Attempts at repair with fibrosis and
angiogenesis (new vessel formation)
 When acute phase cannot be resolved
 Persistent injury or infection (ulcer, TB)
 Prolonged toxic agent exposure (silica)
 Autoimmune disease states (RA, SLE)
The Players (mononuclear
phagocyte system)
 Macrophages
 Scattered all over (microglia, Kupffer cells, sinus
histiocytes, alveolar macrophages, etc.
 Circulate as monocytes and reach site of injury within 24 –
48 hrs and transform
 Become activated by T cell-derived cytokines, endotoxins,
and other products of inflammation
The Players
 T and B lymphocytes
 Antigen-activated (via macrophages and dendritic cells)
 Release macrophage-activating cytokines (in turn,
macrophages release lymphocyte-activating cytokines until
inflammatory stimulus is removed)
 Plasma cells
 Terminally differentiated B cells
The Players
 Produce antibodies
 Eosinophils
 Found especially at sites of parasitic infection, or at
allergic (IgE-mediated) sites
Granulomatous Inflammation
 Clusters of T cell-activated macrophages, which engulf
and surround indigestible foreign bodies (mycobacteria,
H. capsulatum, silica, suture material)
 Resemble squamous cells, therefore called “epithelioid”
granulomas
Lymph Nodes and Lymphatics
 Lymphatics drain tissues
 Flow increased in inflammation
 Antigen to the lymph node
 Toxins, infectious agents also to the node
 Lymphadenitis, lymphangitis
 Usually contained there, otherwise bacteremia ensues
 Tissue-resident macrophages must then prevent overwhelming
infection
Patterns of acute and chronic
inflammation
 Serous
 Watery, protein-poor effusion (e.g., blister)
 Fibrinous
 Fibrin accumulation
 Either entirely removed or becomes fibrotic
 Suppurative
 Presence of pus (pyogenic staph spp.)
 Often walled-off if persistent
Patterns (cont’d)
 Ulceration
 Necrotic and eroded epithelial surface
 Underlying acute and chronic inflammation
 Trauma, toxins, vascular insufficiency
Systemic effects
 Fever
 One of the easily recognized cytokine-mediated (esp. IL-1,
IL-6, TNF) acute-phase reactions including
 Anorexia
 Skeletal muscle protein degradation
 Hypotension
 Leukocytosis
 Elevated white blood cell count
Systemic effects (cont’d)
 Bacterial infection (neutrophilia)
 Parasitic infection (eosinophilia)
 Viral infection (lymphocytosis)
 Chapter 2, “Acute and Chronic Inflammation” in
Robbins’ Basic Pathology, Sixth Edition, pages 25 - 46

Más contenido relacionado

La actualidad más candente (20)

Acute and chronic inflammation
Acute and chronic inflammationAcute and chronic inflammation
Acute and chronic inflammation
 
Cell injury
Cell injuryCell injury
Cell injury
 
Embolism
EmbolismEmbolism
Embolism
 
Acute and chronic inflammation 1 robbins
Acute and chronic inflammation 1  robbinsAcute and chronic inflammation 1  robbins
Acute and chronic inflammation 1 robbins
 
Hemodynamic disorders
Hemodynamic disorders Hemodynamic disorders
Hemodynamic disorders
 
AMYLOIDOSIS
AMYLOIDOSISAMYLOIDOSIS
AMYLOIDOSIS
 
Infarction
InfarctionInfarction
Infarction
 
Tissue healing
Tissue healingTissue healing
Tissue healing
 
Inflammation
InflammationInflammation
Inflammation
 
Thrombosis
ThrombosisThrombosis
Thrombosis
 
Inflammation
Inflammation  Inflammation
Inflammation
 
Morphology of-acute-inflammation
Morphology of-acute-inflammationMorphology of-acute-inflammation
Morphology of-acute-inflammation
 
Inflammation and repair rince
Inflammation and repair rinceInflammation and repair rince
Inflammation and repair rince
 
Patho inflammation
Patho inflammationPatho inflammation
Patho inflammation
 
Acute and chronic inflammation
Acute and chronic inflammationAcute and chronic inflammation
Acute and chronic inflammation
 
Acute inflammation
Acute inflammationAcute inflammation
Acute inflammation
 
Inflamation-Pathology lecture notes
Inflamation-Pathology lecture notesInflamation-Pathology lecture notes
Inflamation-Pathology lecture notes
 
Pathophysiology inflammation and repair
Pathophysiology inflammation and repairPathophysiology inflammation and repair
Pathophysiology inflammation and repair
 
Mechanism of inflammation
Mechanism of inflammationMechanism of inflammation
Mechanism of inflammation
 
Cell injury, Etiology, Pathogenesis, & Morphology of cell Injury
Cell injury, Etiology, Pathogenesis, & Morphology of cell InjuryCell injury, Etiology, Pathogenesis, & Morphology of cell Injury
Cell injury, Etiology, Pathogenesis, & Morphology of cell Injury
 

Similar a Acute and chronic inflammation by Pandian M.

Acute and Chronic Inflammation.PPT
Acute and Chronic Inflammation.PPTAcute and Chronic Inflammation.PPT
Acute and Chronic Inflammation.PPTmalti19
 
Acute chronic inflammation
Acute chronic inflammationAcute chronic inflammation
Acute chronic inflammationDr Alok Tripathi
 
Acute and chronic inflammation (1) / dental implant courses by Indian dental ...
Acute and chronic inflammation (1) / dental implant courses by Indian dental ...Acute and chronic inflammation (1) / dental implant courses by Indian dental ...
Acute and chronic inflammation (1) / dental implant courses by Indian dental ...Indian dental academy
 
Acute and chronic inflammation
Acute and chronic inflammationAcute and chronic inflammation
Acute and chronic inflammationDr Alok Tripathi
 
11 cellular & vascular events in acute inflammation
11 cellular & vascular events in acute inflammation11 cellular & vascular events in acute inflammation
11 cellular & vascular events in acute inflammationDr UAK
 
1.ACUTE AND CHRONIC INFLAMMATION.pptx
1.ACUTE AND CHRONIC INFLAMMATION.pptx1.ACUTE AND CHRONIC INFLAMMATION.pptx
1.ACUTE AND CHRONIC INFLAMMATION.pptxmwalunuym
 
lecture6inflammation-pptx-120913130832-phpapp01.pdf
lecture6inflammation-pptx-120913130832-phpapp01.pdflecture6inflammation-pptx-120913130832-phpapp01.pdf
lecture6inflammation-pptx-120913130832-phpapp01.pdfDeviSneha1
 
Inflammation-and-repair-lecture (1).ppt
Inflammation-and-repair-lecture (1).pptInflammation-and-repair-lecture (1).ppt
Inflammation-and-repair-lecture (1).pptAnjanaTandon3
 
Lecture-inflamation_Engl_.ppt
Lecture-inflamation_Engl_.pptLecture-inflamation_Engl_.ppt
Lecture-inflamation_Engl_.pptBharath Doltade
 
Lecture 6 inflammation.pptx
Lecture 6 inflammation.pptxLecture 6 inflammation.pptx
Lecture 6 inflammation.pptxKizito Robert
 
Inflammation -basics
Inflammation -basicsInflammation -basics
Inflammation -basicsNINU RAJU
 
PROCESS OF INFLAMMATION B.PHARM 2ND SEM.pptx
PROCESS OF INFLAMMATION B.PHARM 2ND SEM.pptxPROCESS OF INFLAMMATION B.PHARM 2ND SEM.pptx
PROCESS OF INFLAMMATION B.PHARM 2ND SEM.pptxsubhamsourajit1
 
Inflammation & cellular response
Inflammation & cellular responseInflammation & cellular response
Inflammation & cellular responseMuhammadasif909
 
Introduction of inflammation
Introduction of inflammationIntroduction of inflammation
Introduction of inflammationshivangimistry3
 
4. acute Inflammation31.08.17 153 series.pptx
4. acute Inflammation31.08.17 153 series.pptx4. acute Inflammation31.08.17 153 series.pptx
4. acute Inflammation31.08.17 153 series.pptxByamugishaJames
 
Mechanism involved in the process of inflammation lecture 5
Mechanism involved in the process of inflammation  lecture 5Mechanism involved in the process of inflammation  lecture 5
Mechanism involved in the process of inflammation lecture 5Archana Mandava
 
Inflammation new.pptx shjssjidjdjksloiyzñn
Inflammation new.pptx shjssjidjdjksloiyzñnInflammation new.pptx shjssjidjdjksloiyzñn
Inflammation new.pptx shjssjidjdjksloiyzñnBekiUje
 

Similar a Acute and chronic inflammation by Pandian M. (20)

Acute and Chronic Inflammation.PPT
Acute and Chronic Inflammation.PPTAcute and Chronic Inflammation.PPT
Acute and Chronic Inflammation.PPT
 
Acute and chronic inflammation(1)
Acute and chronic inflammation(1)Acute and chronic inflammation(1)
Acute and chronic inflammation(1)
 
Acute chronic inflammation
Acute chronic inflammationAcute chronic inflammation
Acute chronic inflammation
 
Acute and chronic inflammation (1) / dental implant courses by Indian dental ...
Acute and chronic inflammation (1) / dental implant courses by Indian dental ...Acute and chronic inflammation (1) / dental implant courses by Indian dental ...
Acute and chronic inflammation (1) / dental implant courses by Indian dental ...
 
Acute and chronic inflammation
Acute and chronic inflammationAcute and chronic inflammation
Acute and chronic inflammation
 
11 cellular & vascular events in acute inflammation
11 cellular & vascular events in acute inflammation11 cellular & vascular events in acute inflammation
11 cellular & vascular events in acute inflammation
 
1.ACUTE AND CHRONIC INFLAMMATION.pptx
1.ACUTE AND CHRONIC INFLAMMATION.pptx1.ACUTE AND CHRONIC INFLAMMATION.pptx
1.ACUTE AND CHRONIC INFLAMMATION.pptx
 
lecture6inflammation-pptx-120913130832-phpapp01.pdf
lecture6inflammation-pptx-120913130832-phpapp01.pdflecture6inflammation-pptx-120913130832-phpapp01.pdf
lecture6inflammation-pptx-120913130832-phpapp01.pdf
 
Inflammation-and-repair-lecture (1).ppt
Inflammation-and-repair-lecture (1).pptInflammation-and-repair-lecture (1).ppt
Inflammation-and-repair-lecture (1).ppt
 
Lecture-inflamation_Engl_.ppt
Lecture-inflamation_Engl_.pptLecture-inflamation_Engl_.ppt
Lecture-inflamation_Engl_.ppt
 
Acute inflammation
Acute inflammationAcute inflammation
Acute inflammation
 
Lecture 6 inflammation.pptx
Lecture 6 inflammation.pptxLecture 6 inflammation.pptx
Lecture 6 inflammation.pptx
 
Inflammation -basics
Inflammation -basicsInflammation -basics
Inflammation -basics
 
PROCESS OF INFLAMMATION B.PHARM 2ND SEM.pptx
PROCESS OF INFLAMMATION B.PHARM 2ND SEM.pptxPROCESS OF INFLAMMATION B.PHARM 2ND SEM.pptx
PROCESS OF INFLAMMATION B.PHARM 2ND SEM.pptx
 
Inflammation & cellular response
Inflammation & cellular responseInflammation & cellular response
Inflammation & cellular response
 
Introduction of inflammation
Introduction of inflammationIntroduction of inflammation
Introduction of inflammation
 
4. acute Inflammation31.08.17 153 series.pptx
4. acute Inflammation31.08.17 153 series.pptx4. acute Inflammation31.08.17 153 series.pptx
4. acute Inflammation31.08.17 153 series.pptx
 
Mechanism involved in the process of inflammation lecture 5
Mechanism involved in the process of inflammation  lecture 5Mechanism involved in the process of inflammation  lecture 5
Mechanism involved in the process of inflammation lecture 5
 
Inflammation
Inflammation Inflammation
Inflammation
 
Inflammation new.pptx shjssjidjdjksloiyzñn
Inflammation new.pptx shjssjidjdjksloiyzñnInflammation new.pptx shjssjidjdjksloiyzñn
Inflammation new.pptx shjssjidjdjksloiyzñn
 

Más de Pandian M

Thalamus .ppt
Thalamus .pptThalamus .ppt
Thalamus .pptPandian M
 
Pulmonary Surfactant for MBBS .pptx
Pulmonary Surfactant for MBBS .pptxPulmonary Surfactant for MBBS .pptx
Pulmonary Surfactant for MBBS .pptxPandian M
 
What does it mean by Patient.pptx
What does it mean by Patient.pptxWhat does it mean by Patient.pptx
What does it mean by Patient.pptxPandian M
 
WBC formation and regulation.pptx
WBC formation and regulation.pptxWBC formation and regulation.pptx
WBC formation and regulation.pptxPandian M
 
Introduction to CVS ZMCh.pptx
Introduction to CVS ZMCh.pptxIntroduction to CVS ZMCh.pptx
Introduction to CVS ZMCh.pptxPandian M
 
Properties of CM, Plateau Potential & Pacemaker.pptx
Properties of  CM, Plateau Potential & Pacemaker.pptxProperties of  CM, Plateau Potential & Pacemaker.pptx
Properties of CM, Plateau Potential & Pacemaker.pptxPandian M
 
Urine formation 2 zydus.pptx
Urine formation 2 zydus.pptxUrine formation 2 zydus.pptx
Urine formation 2 zydus.pptxPandian M
 
Urine formation -1 zydus.pptx
Urine formation -1 zydus.pptxUrine formation -1 zydus.pptx
Urine formation -1 zydus.pptxPandian M
 
Bladder, Micturition and Applied 2023.pptx
Bladder, Micturition and Applied 2023.pptxBladder, Micturition and Applied 2023.pptx
Bladder, Micturition and Applied 2023.pptxPandian M
 
THE COUNTERCURRENT.pptx
THE COUNTERCURRENT.pptxTHE COUNTERCURRENT.pptx
THE COUNTERCURRENT.pptxPandian M
 
ARTIFICIAL KIDNEY , DIALYSIS AND RENAL TRANSPLANT.ppt
ARTIFICIAL KIDNEY , DIALYSIS AND RENAL TRANSPLANT.pptARTIFICIAL KIDNEY , DIALYSIS AND RENAL TRANSPLANT.ppt
ARTIFICIAL KIDNEY , DIALYSIS AND RENAL TRANSPLANT.pptPandian M
 
Applied aspects of Kidney and RFT by Dr. MP.pptx
Applied aspects of Kidney and RFT by Dr. MP.pptxApplied aspects of Kidney and RFT by Dr. MP.pptx
Applied aspects of Kidney and RFT by Dr. MP.pptxPandian M
 
Neuromuscular Junction (NMJ).pptx
Neuromuscular Junction (NMJ).pptxNeuromuscular Junction (NMJ).pptx
Neuromuscular Junction (NMJ).pptxPandian M
 
Degeneration & regeneration of nerve fiber.ppt by Dr. PANDIAN M.
Degeneration & regeneration of nerve fiber.ppt by Dr. PANDIAN M.Degeneration & regeneration of nerve fiber.ppt by Dr. PANDIAN M.
Degeneration & regeneration of nerve fiber.ppt by Dr. PANDIAN M.Pandian M
 
Haemoglobin.pptx
Haemoglobin.pptxHaemoglobin.pptx
Haemoglobin.pptxPandian M
 
composition of blood - BPTH 2022.pptx
composition of blood - BPTH 2022.pptxcomposition of blood - BPTH 2022.pptx
composition of blood - BPTH 2022.pptxPandian M
 
composition of blood.pptx
composition of blood.pptxcomposition of blood.pptx
composition of blood.pptxPandian M
 
Determination of WBC count by Dr. Pandian M..pptx
Determination of WBC count by Dr. Pandian M..pptxDetermination of WBC count by Dr. Pandian M..pptx
Determination of WBC count by Dr. Pandian M..pptxPandian M
 
PLATELET COUNT by Dr. Pandian M .pptx
PLATELET COUNT by Dr. Pandian M .pptxPLATELET COUNT by Dr. Pandian M .pptx
PLATELET COUNT by Dr. Pandian M .pptxPandian M
 
Growth by Dr. Pandian M.
Growth by Dr. Pandian M.Growth by Dr. Pandian M.
Growth by Dr. Pandian M.Pandian M
 

Más de Pandian M (20)

Thalamus .ppt
Thalamus .pptThalamus .ppt
Thalamus .ppt
 
Pulmonary Surfactant for MBBS .pptx
Pulmonary Surfactant for MBBS .pptxPulmonary Surfactant for MBBS .pptx
Pulmonary Surfactant for MBBS .pptx
 
What does it mean by Patient.pptx
What does it mean by Patient.pptxWhat does it mean by Patient.pptx
What does it mean by Patient.pptx
 
WBC formation and regulation.pptx
WBC formation and regulation.pptxWBC formation and regulation.pptx
WBC formation and regulation.pptx
 
Introduction to CVS ZMCh.pptx
Introduction to CVS ZMCh.pptxIntroduction to CVS ZMCh.pptx
Introduction to CVS ZMCh.pptx
 
Properties of CM, Plateau Potential & Pacemaker.pptx
Properties of  CM, Plateau Potential & Pacemaker.pptxProperties of  CM, Plateau Potential & Pacemaker.pptx
Properties of CM, Plateau Potential & Pacemaker.pptx
 
Urine formation 2 zydus.pptx
Urine formation 2 zydus.pptxUrine formation 2 zydus.pptx
Urine formation 2 zydus.pptx
 
Urine formation -1 zydus.pptx
Urine formation -1 zydus.pptxUrine formation -1 zydus.pptx
Urine formation -1 zydus.pptx
 
Bladder, Micturition and Applied 2023.pptx
Bladder, Micturition and Applied 2023.pptxBladder, Micturition and Applied 2023.pptx
Bladder, Micturition and Applied 2023.pptx
 
THE COUNTERCURRENT.pptx
THE COUNTERCURRENT.pptxTHE COUNTERCURRENT.pptx
THE COUNTERCURRENT.pptx
 
ARTIFICIAL KIDNEY , DIALYSIS AND RENAL TRANSPLANT.ppt
ARTIFICIAL KIDNEY , DIALYSIS AND RENAL TRANSPLANT.pptARTIFICIAL KIDNEY , DIALYSIS AND RENAL TRANSPLANT.ppt
ARTIFICIAL KIDNEY , DIALYSIS AND RENAL TRANSPLANT.ppt
 
Applied aspects of Kidney and RFT by Dr. MP.pptx
Applied aspects of Kidney and RFT by Dr. MP.pptxApplied aspects of Kidney and RFT by Dr. MP.pptx
Applied aspects of Kidney and RFT by Dr. MP.pptx
 
Neuromuscular Junction (NMJ).pptx
Neuromuscular Junction (NMJ).pptxNeuromuscular Junction (NMJ).pptx
Neuromuscular Junction (NMJ).pptx
 
Degeneration & regeneration of nerve fiber.ppt by Dr. PANDIAN M.
Degeneration & regeneration of nerve fiber.ppt by Dr. PANDIAN M.Degeneration & regeneration of nerve fiber.ppt by Dr. PANDIAN M.
Degeneration & regeneration of nerve fiber.ppt by Dr. PANDIAN M.
 
Haemoglobin.pptx
Haemoglobin.pptxHaemoglobin.pptx
Haemoglobin.pptx
 
composition of blood - BPTH 2022.pptx
composition of blood - BPTH 2022.pptxcomposition of blood - BPTH 2022.pptx
composition of blood - BPTH 2022.pptx
 
composition of blood.pptx
composition of blood.pptxcomposition of blood.pptx
composition of blood.pptx
 
Determination of WBC count by Dr. Pandian M..pptx
Determination of WBC count by Dr. Pandian M..pptxDetermination of WBC count by Dr. Pandian M..pptx
Determination of WBC count by Dr. Pandian M..pptx
 
PLATELET COUNT by Dr. Pandian M .pptx
PLATELET COUNT by Dr. Pandian M .pptxPLATELET COUNT by Dr. Pandian M .pptx
PLATELET COUNT by Dr. Pandian M .pptx
 
Growth by Dr. Pandian M.
Growth by Dr. Pandian M.Growth by Dr. Pandian M.
Growth by Dr. Pandian M.
 

Último

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 

Último (20)

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 

Acute and chronic inflammation by Pandian M.

  • 3. Introduction  Injurious stimuli cause a protective vascular connective tissue reaction called “inflammation”  Dilute  Destroy  Isolate  Initiate repair  Acute and chronic forms
  • 4. Acute inflammation  Immediate and early response to tissue injury (physical, chemical, microbiologic, etc.)  Vasodilation  Vascular leakage and edema  Leukocyte emigration (mostly PMNs)
  • 5. Vasodilation  Brief arteriolar vasoconstriction followed by vasodilation  Accounts for warmth and redness  Opens microvascular beds  Increased intravascular pressure causes an early transudate (protein-poor filtrate of plasma) into interstitium (vascular permeability still not increased yet)
  • 6. Vascular leakage  Vascular permeability (leakiness) commences  Transudate gives way to exudate (protein-rich)  Increases interstitial osmotic pressure contributing to edema (water and ions)
  • 7. Vascular leakage  Five mechanisms known to cause vascular leakiness  Histamines, bradykinins, leukotrienes cause an early, brief (15 – 30 min.) immediate transient response in the form of endothelial cell contraction that widens intercellular gaps of venules (not arterioles, capillaries)
  • 8. Vascular leakage  Cytokine mediators (TNF, IL-1) induce endothelial cell junction retraction through cytoskeleton reorganization (4 – 6 hrs post injury, lasting 24 hrs or more)  Severe injuries may cause immediate direct endothelial cell damage (necrosis, detachment) making them leaky until they are repaired (immediate sustained response), or may cause delayed damage as in thermal or UV injury,
  • 9. Vascular leakage  (cont’d) or some bacterial toxins (delayed prolonged leakage)  Marginating and endothelial cell-adherent leukocytes may pile-up and damage the endothelium through activation and release of toxic oxygen radicals and proteolytic enzymes (leukocyte-dependent endothelial cell injury) making the vessel leaky
  • 10. Vascular leakage  Certain mediators (VEGF) may cause increased transcytosis via intracellular vesicles which travel from the luminal to basement membrane surface of the endothelial cell  All or any combination of these events may occur in response to a given stimulus
  • 11. Leukocyte cellular events  Leukocytes leave the vasculature routinely through the following sequence of events:  Margination and rolling  Adhesion and transmigration  Chemotaxis and activation  They are then free to participate in:  Phagocytosis and degranulation  Leukocyte-induced tissue injury
  • 12. Margination and Rolling  With increased vascular permeability, fluid leaves the vessel causing leukocytes to settle-out of the central flow column and “marginate” along the endothelial surface  Endothelial cells and leukocytes have complementary surface adhesion molecules which briefly stick and release causing the leukocyte to roll along the endothelium like a tumbleweed until it eventually comes to a stop as mutual adhesion reaches a peak
  • 13. Margination and Rolling  Early rolling adhesion mediated by selectin family:  E-selectin (endothelium), P-selectin (platelets, endothelium), L-selectin (leukocytes) bind other surface molecules (i.e.,CD34, Sialyl-Lewis X-modified GP) that are upregulated on endothelium by cytokines (TNF, IL-1) at injury sites
  • 14. Adhesion  Rolling comes to a stop and adhesion results  Other sets of adhesion molecules participate:  Endothelial: ICAM-1, VCAM-1  Leukocyte: LFA-1, Mac-1, VLA-4 (ICAM-1 binds LFA-1/Mac-1, VCAM-1 binds VLA-4)  Ordinarily down-regulated or in an inactive conformation, but inflammation alters this
  • 15. Transmigration (diapedesis)  Occurs after firm adhesion within the systemic venules and pulmonary capillaries via PECAM –1 (CD31)  Must then cross basement membrane  Collagenases  Integrins
  • 16. Transmigration (diapedesis)  Early in inflammatory response mostly PMNs, but as cytokine and chemotactic signals change with progression of inflammatory response, alteration of endothelial cell adhesion molecule expression activates other populations of leukocytes to adhere (monocytes, lymphocytes, etc)
  • 17. Chemotaxis  Leukocytes follow chemical gradient to site of injury (chemotaxis)  Soluble bacterial products  Complement components (C5a)  Cytokines (chemokine family e.g., IL-8)  LTB4 (AA metabolite)  Chemotactic agents bind surface receptors inducing calcium mobilization and assembly of cytoskeletal contractile elements
  • 18. Chemotaxis and Activation  Leukocytes:  extend pseudopods with overlying surface adhesion molecules (integrins) that bind ECM during chemotaxis  undergo activation:  Prepare AA metabolites from phospholipids  Prepare for degranulation and release of lysosomal enzymes (oxidative burst)  Regulate leukocyte adhesion molecule affinity as needed
  • 19. Phagocytosis and Degranulation  Once at site of injury, leukocytes:  Recognize and attach  Engulf (form phagocytic vacuole)  Kill (degrade)
  • 20. Recognition and Binding  Opsonized by serum complement, immunoglobulin (C3b, Fc portion of IgG)  Corresponding receptors on leukocytes (FcR, CR1, 2, 3) leads to binding
  • 21. Phagocytosis and Degranulation  Triggers an oxidative burst (next slide) engulfment and formation of vacuole which fuses with lysosomal granule membrane (phagolysosome)  Granules discharge within phagolysosome and extracellularly (degranulation)
  • 22. Oxidative burst  Reactive oxygen species formed through oxidative burst that includes:  Increased oxygen consumption  Glycogenolysis  Increased glucose oxidation  Formation of superoxide ion  2O2 + NADPH  2O2 -rad + NADP+ + H+ (NADPH oxidase)  O2 + 2H+  H2O2 (dismutase)
  • 23. Reactive oxygen species  Hydrogen peroxide alone insufficient  MPO (azurophilic granules) converts hydrogen peroxide to HOCl- (in presence of Cl- ), an oxidant/antimicrobial agent  Therefore, PMNs can kill by halogenation, or lipid/protein peroxidation
  • 24. Degradation and Clean-up  Reactive end-products only active within phagolysosome  Hydrogen peroxide broken down to water and oxygen by catalase  Dead microorganisms degraded by lysosomal acid hydrolases
  • 25. Leukocyte granules  Other antimicrobials in leukocyte granules:  Bactericidal permeability increasing protein (BPI)  Lysozyme  Lactoferrin  Defensins (punch holes in membranes)
  • 26. Leukocyte-induced tissue injury  Destructive enzymes may enter extracellular space in event of:  Premature degranulation  Frustrated phagocytosis (large, flat)  Membranolytic substances (urate crystals)  Persistent leukocyte activation (RA, emphysema)
  • 27. Defects of leukocyte function  Defects of adhesion:  LFA-1 and Mac-1 subunit defects lead to impaired adhesion (LAD-1)  Absence of sialyl-Lewis X, and defect in E- and P-selectin sugar epitopes (LAD-2)  Defects of chemotaxis/phagocytosis:  Microtubule assembly defect leads to impaired locomotion and lysosomal degranulation (Chediak-Higashi Syndrome)
  • 28. Defects of leukocyte function  Defects of microbicidal activity:  Deficiency of NADPH oxidase that generates superoxide, therefore no oxygen-dependent killing mechanism (chronic granulomatous disease)
  • 29. Chemical mediators  Plasma-derived:  Complement, kinins, coagulation factors  Many in “pro-form” requiring activation (enzymatic cleavage)  Cell-derived:  Preformed, sequestered and released (mast cell histamine)  Synthesized as needed (prostaglandin)
  • 30. Chemical mediators  May or may not utilize a specific cell surface receptor for activity  May also signal target cells to release other effector molecules that either amplify or inhibit initial response (regulation)  Are tightly regulated:  Quickly decay (AA metabolites), are inactivated enzymatically (kininase), or are scavenged (antioxidants)
  • 31. Specific mediators  Vasoactive amines  Histamine: vasodilation and venular endothelial cell contraction, junctional widening; released by mast cells, basophils, platelets in response to injury (trauma, heat), immune reactions (IgE-mast cell FcR), anaphylatoxins (C3a, C5a fragments), cytokines (IL-1, IL-8), neuropeptides, leukocyte-derived histamine-releasing peptides
  • 32. Specific mediators  Serotonin: vasodilatory effects similar to those of histamine; platelet dense-body granules; release triggered by platelet aggregation  Plasma proteases  Clotting system  Complement  Kinins
  • 33. Clotting cascade  Cascade of plasma proteases  Hageman factor (factor XII)  Collagen, basement membrane, activated platelets converts XII to XIIa (active form)  Ultimately converts soluble fibrinogen to insoluble fibrin clot  Factor XIIa simultaneously activates the “brakes” through the fibrinolytic system to prevent continuous clot propagation
  • 34. Kinin system  Leads to formation of bradykinin from cleavage of precursor (HMWK)  Vascular permeability  Arteriolar dilation  Non-vascular smooth muscle contraction (e.g., bronchial smooth muscle)  Causes pain  Rapidly inactivated (kininases)
  • 35. Complement system  Components C1-C9 present in inactive form  Activated via classic (C1) or alternative (C3) pathways to generate MAC (C5 – C9) that punch holes in microbe membranes  In acute inflammation  Vasodilation, vascular permeability, mast cell degranulation (C3a, C5a)  Leukocyte chemotaxin, increases integrin avidity (C5a)  As an opsonin, increases phagocytosis (C3b, C3bi)
  • 36. Specific Mediators  Arachidonic acid metabolites (eicosanoids)  Prostaglandins and thromboxane: via cyclooxygenase pathway; cause vasodilation and prolong edema; but also protective (gastric mucosa); COX blocked by aspirin and NSAIDS
  • 37. Specific Mediators  Leukotrienes: via lipoxygenase pathway; are chemotaxins, vasoconstrictors, cause increased vascular permeability, and bronchospasm  PAF (platelet activating factor)  Derived also from cell membrane phospholipid, causes vasodilation, increased vascular permeability, increases leukocyte adhesion (integrin conformation)
  • 38. More specific mediators  Cytokines  Protein cell products that act as a message to other cells, telling them how to behave.  IL-1, TNF- and -, IFN- are especially important in inflammation.  Increase endothelial cell adhesion molecule expression, activation and aggregation of PMNs, etc., etc., etc.
  • 39. Specific mediators  Nitric Oxide  short-acting soluble free-radical gas with many functions  Produced by endothelial cells, macrophages, causes:  Vascular smooth muscle relaxation and vasodilation  Kills microbes in activated macrophages  Counteracts platelet adhesion, aggregation, and degranulation
  • 40. Specific mediators  Lysosomal components  Leak from PMNs and macrophages after demise, attempts at phagocytosis, etc.  Acid proteases (only active within lysosomes).  Neutral proteases such as elastase and collagenase are destructive in ECM.  Counteracted by serum and ECM anti-proteases.
  • 41. Possible outcomes of acute inflammation  Complete resolution  Little tissue damage  Capable of regeneration  Scarring (fibrosis)  In tissues unable to regenerate  Excessive fibrin deposition organized into fibrous tissue
  • 42. Outcomes (cont’d)  Abscess formation occurs with some bacterial or fungal infections  Progression to chronic inflammation (next)
  • 43. Chronic inflammation  Lymphocyte, macrophage, plasma cell (mononuclear cell) infiltration  Tissue destruction by inflammatory cells  Attempts at repair with fibrosis and angiogenesis (new vessel formation)  When acute phase cannot be resolved  Persistent injury or infection (ulcer, TB)  Prolonged toxic agent exposure (silica)  Autoimmune disease states (RA, SLE)
  • 44. The Players (mononuclear phagocyte system)  Macrophages  Scattered all over (microglia, Kupffer cells, sinus histiocytes, alveolar macrophages, etc.  Circulate as monocytes and reach site of injury within 24 – 48 hrs and transform  Become activated by T cell-derived cytokines, endotoxins, and other products of inflammation
  • 45. The Players  T and B lymphocytes  Antigen-activated (via macrophages and dendritic cells)  Release macrophage-activating cytokines (in turn, macrophages release lymphocyte-activating cytokines until inflammatory stimulus is removed)  Plasma cells  Terminally differentiated B cells
  • 46. The Players  Produce antibodies  Eosinophils  Found especially at sites of parasitic infection, or at allergic (IgE-mediated) sites
  • 47. Granulomatous Inflammation  Clusters of T cell-activated macrophages, which engulf and surround indigestible foreign bodies (mycobacteria, H. capsulatum, silica, suture material)  Resemble squamous cells, therefore called “epithelioid” granulomas
  • 48. Lymph Nodes and Lymphatics  Lymphatics drain tissues  Flow increased in inflammation  Antigen to the lymph node  Toxins, infectious agents also to the node  Lymphadenitis, lymphangitis  Usually contained there, otherwise bacteremia ensues  Tissue-resident macrophages must then prevent overwhelming infection
  • 49. Patterns of acute and chronic inflammation  Serous  Watery, protein-poor effusion (e.g., blister)  Fibrinous  Fibrin accumulation  Either entirely removed or becomes fibrotic  Suppurative  Presence of pus (pyogenic staph spp.)  Often walled-off if persistent
  • 50. Patterns (cont’d)  Ulceration  Necrotic and eroded epithelial surface  Underlying acute and chronic inflammation  Trauma, toxins, vascular insufficiency
  • 51. Systemic effects  Fever  One of the easily recognized cytokine-mediated (esp. IL-1, IL-6, TNF) acute-phase reactions including  Anorexia  Skeletal muscle protein degradation  Hypotension  Leukocytosis  Elevated white blood cell count
  • 52. Systemic effects (cont’d)  Bacterial infection (neutrophilia)  Parasitic infection (eosinophilia)  Viral infection (lymphocytosis)
  • 53.  Chapter 2, “Acute and Chronic Inflammation” in Robbins’ Basic Pathology, Sixth Edition, pages 25 - 46